The United Kingdom and the United States have announced a major trade agreement that will preserve zero duties on UK medicine shipments being sold in the American market.
Agreement Details of the Deal
As part of the deal, the UK has committed to boost spending on medicines through the NHS. This move guarantees that duties on these vital exports will be held at zero for a duration of three years.
This deal follows previous statements to significantly raise tariffs on patented pharmaceutical products, with potential rates floated reaching 100%.
"This deal with the United Kingdom strengthens the worldwide climate for innovative medicines and brings much-needed equity to U.S.–U.K. pharmaceutical trade," an announcement noted.
Economic Importance
Drugs are one of the UK's biggest exports to the United States, which is clearly the primary market for large British pharmaceutical firms.
Statistics indicate that in the one-year period prior to last September, the UK shipped drugs valued at billions to the US. This value made up a significant portion of total UK exports in that period.
"This guarantee protects jobs, stimulates funding and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a minister commented.
Key British Pledges
The deal includes several key pledges from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to raise overall public funding on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. Previously, refunds were more than 20%.
Recent Tensions
The pact follows a protracted row between the drug companies and the UK government over drug pricing and approval rates.
The disagreement were exacerbated by claims that US customers were charged significantly more for the equivalent treatments than people in the other developed nations.
In recent months, several large manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been pledged toward US facilities.
One official publicly accepted that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a proportion of its resources over the last ten years.
